What happened with BWAY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Brainsway Ltd.’s Deep TMS systems let doctors treat patients in their offices using magnetic pulses delivered through an H-Coil helmet to stimulate brain regions. In the United States, the FDA-authorized uses are major depressive disorder, including associated anxiety symptoms, obsessive-compulsive disorder and smoking addiction; the company may not promote other uses.
Doctors, mental-health clinics and hospitals pay Brainsway to buy or lease the equipment. System sales bring in most revenue, followed by leases, which generally allow unlimited use in the United States. The United States supplies most of the company’s revenue, and one large customer operating mental-health clinics across multiple states accounts for a significant share.
The business depends entirely on Deep TMS and on providers adopting the treatment. Insurance reimbursement matters because it helps patients afford sessions and providers cover equipment costs. Coverage for depression and obsessive-compulsive disorder comes with eligibility requirements and varies by insurer; smoking-addiction treatment has no third-party coverage.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BrainsWay’s results hinge on psychiatric clinics adopting Deep TMS and insurers reimbursing treatment, with MagVenture, Magstim and Nexstim adding direct competition beyond this list.
Neuronetics competes for the psychiatric providers that buy or lease BrainsWay’s Deep TMS systems by selling them NeuroStar systems, and its ownership of Greenbrook clinics can limit BrainsWay’s placement opportunities. Watch its clinic and recurring treatment-session revenue, which together provide most of its revenue, for signs of TMS adoption among depression providers.
LivaNova PLC offers an alternative to BrainsWay’s noninvasive Deep TMS by selling implanted devices that stimulate the vagus nerve to treat difficult-to-treat depression. Watch adoption and reimbursement of that depression treatment, rather than its heart-lung equipment or epilepsy devices, for the competitive read-through to BrainsWay.
Neuronetics, Inc. earningsSTIM
Neuronetics’ report will show whether psychiatry providers are adopting TMS for depression, as it competes with BrainsWay for system placements and operates Greenbrook clinics.
Watch whether Neuronetics’ clinic revenue and recurring revenue from treatment sessions both grow. Growth in both would show clinics are sustaining TMS treatment activity, which could support demand for BrainsWay systems; weakness in both would point to a harder market for placements and treatment use.
Brainsway Ltd. earningsThis company
BrainsWay’s report will show whether psychiatry providers are buying or leasing enough Deep TMS systems to grow sales without squeezing margins.
Read system sales alongside lease revenue, then check gross margin—the share of revenue left after direct costs. Rising sales with steady leases and margin would show clinics are adding systems while installed units keep earning fees. Weaker sales or leases, or costs that squeeze margin, would show growth is harder to sustain.
